Corporate News

7th Anniversary Q&A 5: How to Break Global Regulatory Barriers and Achieve One Single Study for Multi‑Country IND Filings?
7th Anniversary Q&A 4: From Isolated Capabilities to a Symbiotic Ecosystem — How Is Medicilon Building a New Drug Innovation Ecosystem?
From Shanghai Jiao Tong University Lab toward IND: Medicilon Accelerates PentoGen’s Oligonucleotide Pipeline
Medicilon presented the ” Excellence in Client Partnership Award ” to it long-time collaboration partner Revolution Medicines
Breaking New Ground in Alzheimer’s Disease! Medicilon Supports Hengrui Pharma’s SHR-3201 Injection to Secure Clinical Trial Approval
Breaking the “King of Cancer”: First-in-Class ADC MC001. Medicilon Supports Partner Medicovestor to Secure FDA IND Clearance

Events

Nov. 16(Mon.) - 19 (Thu.), 2026. Venue: Tsukuba International Congress Center, Tsukuba, Japan.
JSSX 2026
Oct. 15 (Thu.) - 16 (Fri.), 2026. Venue, Alpensia Resort, Pyeongchang, South Korea.
50th Korean Society of Nonclinical Studies (KSNS)
Oct. 7 (Wed.) - 9 (Fri.), 2026 10:00-17:00. Venue, PACIFICO Yokohama.
BIOJAPAN 2026
Basel, Switzerland from September 6-10, 2026
EFMC-ISMC 2026
Date: August 27-28, 2026
Venue:The Westin Seoul Parnas, South Korea - Medicilon Booth #6
4th SMC and AimedBio ADC Conference
Date: August 23-27, 2026
Venue: McCormick Place Convention Center, Chicago, IL - Medicilon Booth #400
ACS Fall 2026

Medicilon Academy

【Case Study】New Approach Methods NAMs
【Case Study】Route, Solid-State, and Impurity Optimization (Small-Molecule API)
【Case Study】IND Completion in 12 Months (Small-Molecule NCE)
Boston Non-Tumor Models Innovation
【White Paper】Navigating the DMPK Gauntlet: A Strategic Analysis of the Interconnected Challenges Shaping the Future of Drug Development
【White Paper】Patient-Derived Xenograft Organoids: Advancements and Applications in Precision Oncology

Digital Materials

NAMs: MODEL-INFORMED DRUG DEVELOPMENT BASED PREDICTION BY INTEGRATING AI-ADMET WITH PBPK
A Sensitive LC–MS Bioanalytical Method for Simultaneous Quantification of Structurally Similar Cyclic Tetrapeptides at the Picogram Level (Download)
Quantification of antibody-Conjugated Drug in Cleavable ADCs: A Universal, Automated, and Cost-Effective LC-MS/MS Platform (Download)
Leveraging a Humanized SLE Mouse Model to Evaluate Next-Generation Immune-Cell-Targeted Therapeutics (Download)
Integrated Mass Spectrometric Workflows Enabling Next-Generation Conjugate Therapeutics in Cancer Research (Download)
From Sequence Design to AOC Production Medicilon’ s End-to-End RNAi Development Platform (Download)

Search Medicilon

Preclinical CRO

7th Anniversary Q&A 5: How to Break Global Regulatory Barriers and Achieve One Single Study for Multi‑Country IND Filings?

Preclinical CRO

7th Anniversary Q&A 4: From Isolated Capabilities to a Symbiotic Ecosystem — How Is Medicilon Building a New Drug Innovation Ecosystem?

Preclinical CRO

From Shanghai Jiao Tong University Lab toward IND: Medicilon Accelerates PentoGen’s Oligonucleotide Pipeline

Contact Medicilon

Name(Required)
Address(Required)